This session will cover different perspectives of translational science and new models of asset development for University based intellectual property. Panelists include senior executives of two different models of development, one a for profit investment fund directly managed by faculty members of Stanford University , the other a wholly owned non-profit drug development subsidiary of Emory University.

After receiving his medical degree from the University of Tennessee Health Sciences Center in Memphis Dr. Eaves completed his general surgery residency at the University of Texas Southwestern Medical Center in Dallas in 1992. He then relocated to Atlanta, Georgia where he completed his plastic surgery training in 1994. At that time he joined the faculty of Emory University School of Medicine and simultaneously was undertook the first fellowship in minimally invasive and aesthetic plastic surgery. Along with his co-authors he published the first textbook on the subject, Endoscopic Plastic Surgery, in 1995.

Leaving Emory to join Charlotte Plastic Surgery in 1997 Dr. Eaves has maintained an active participation in academic plastic surgery with focuses on aesthetic plastic surgery, endoscopic plastic surgery, breast reconstruction, breast and body contouring, plastic surgery of the massive weight loss patient, and patient safety and evidence based medicine. He has published numerous articles and videos on these subjects and has participated in plastic surgery education around the world. He returned to Emory in 2013 to head the new, multidisciplinary Emory Aesthetic Center.

Dr. Eaves has also been active within the American Society for Aesthetic Plastic Surgery where he was President in 2010-2011.. He has also served as Administrative Commissioner, Treasurer, and has chaired numerous committees including the Patient Safety Committee, the Candidate Liaison Committee, and the Finance and Investment Committee. He is a recipient of several awards from ASAPS including the Sherrell J. Aston Award, the Lockwood Award, and was twice recipient of the Simon Fredricks Award. He has an active interest and current projects in Evidence Based Medicine, Patient Safety, Systems and Process Improvement, alongside numerous clinical areas.

"Monte" has a longstanding interest in medical device innovation, designing the some of the first endoscopic systems for plastic surgery. He was co-inventor of the first endoscopic saphenous vein harvest system which was developed at Emory and commercialized in 1996 by Ethicon Endosurgery, a Johnson & Johnson company, and is still being sold under the DataScope label. In 2013 he founded EMRGE, LLC to commercialize three new IP lines related to wound care, wound closure, and adhesive technology applications. Monte has three children and his wife (Gabriele Miotto, MD) is also a plastic surgery now working at Emory.

Jack TillmanAssistant Vice President for Research and Real EstateExecutive Director, Emory Innovations, Inc.

Mr. Tillman supports the leadership teams of Emory across programmatic and corporate domains in strategic development and implementation. His work is focused on creating economic value for Emory by implementing enterprise strategies, integrating research with healthcare, commercializing intellectual capital and know-how, enhancing translational science, and consolidating and optimizing corporate functions.

In addition to his regular work with Emory, Jack holds various leadership positions with cooperative entities including Emory Innovations, Inc., EmTech, Inc. and T3 Labs, Inc. Under his leadership, each of these companies is engaged in non-traditional and non-academic enterprise with missions to support and enhance broader goals of Emory as well as Georgia Tech in the case of EmTech.

Dr. Geoffrey C. Gurtner is the Johnson and Johnson Professor of Surgery and Materials Science and Engineering (by courtesy) at Stanford University. He also serves as the Associate Chairman for Research in the Department of Surgery. Dr. Gurtner is a magna cum laude graduate of Dartmouth College and an AOA graduate of the University of California-San Francisco School of Medicine. He completed a general surgery residency at the Massachusetts General Hospital, a plastic surgery residency at the NYU School of Medicine and received advanced training in microsurgery at the University of Texas-MD Anderson Cancer Center. He is the author of over 180 peer-reviewed publications in both the scientific and surgical literature. He is an Editor for two major textbooks in the field:Grabb & Smith’sPlasticSurgery and Plastic Surgery (Third Edition). Dr. Gurtner was awarded the James Barrett Brown Award (for best paper in plastic surgery) in both 2009 and 2010 and has been named “researcher of the year” by the ASPS, AAPS and numerous other professional organizations. Dr. Gurtner runs an NIH and DoD funded laboratory that examines how physical stimuli (mechanical and chemical) alter the human response to injury. This has led to the development of novel biomedical technologies for which Dr. Gurtner has received 10 issued patents with over 40 pending patent applications.

Dr. Gurtner has also founded several venture backed start-up companies, including Neodyne Biosciences (www.neodynebio.com) and Arresto Biosciences. Dr. Gurtner is also a founding partner atTautona Group (www.tautonagroup.com), an early stage life science fund that has created novel biomedical technologies that have been sold to industry leading companies, including Novadaq (NASDAQ:NVDQ), Allergan (NYSE:AGN) and KCI (San Antonio, TX).

George earned his bachelors, masters and doctoral degrees in chemistry from Emory University and has returned to his alma mater as Director of EIDD and CEO of DRIVE, a new not-for-profit company wholly owned by Emory University but with the independence to run like a biotechnology company. He has three decades of industry experience – including as director of chemistry and virology at Burroughs Wellcome Co., worldwide director of research process and deputy therapeutic head for antiviral research at GlaxoWellcome, EVP (R&D) of Triangle Pharmaceuticals, Inc., which was acquired by Gilead in 2002, and more recently as President, and CEO of Chimerix, Inc. (NASDAQ:CMRX). Dr. Painter has published 91 scientific papers and is co/inventor on more than 45 patents, six of which have led to approved, commercially available drugs or combinations of drugs for the treatment of HIV and hepatitis B. He has led international drug development teams that generated data for nine IND applications and three NDAs.

Quick Links

Quick Links

Stay Social with @Georgia_BioConference #Summit2014

The annual Georgia Bio Innovation Summit (previously the Life Sciences Summit) is presented by Georgia Bio, www.gabio.org. The Summit provides a forum for Georgia’s bioscience community from industry, academia and government to discuss major trends and issues, including topics related to scientific research, product development, financing, business development and public policy.